Chemed price to free cash flow CHE
Market value divided by free cash flow over the last twelve months, since 2011.
- Today, Nov 2, 2026
- 21.9×
- 10-year median
- 27.0×
- Against its 10-year history
- 30th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 14.8× to 58.4×
- Peer median
- 22.1×
Chemed's price to free cash flow is 21.9× as of Nov 2, 2026.
That is below its ten-year median of 27.0×, lower than on 70% of days in the last ten years.
Over that time it ranged from 14.8× in Jun 2026 to 58.4× in May 2018.
The median for 10 hospital and care facility stocks of a similar size is 22.1×.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 21.9× | 14.8× | 22.3× |
| 2025 | 17.0× | 16.4× | 26.9× |
| 2024 | 25.1× | 25.1× | 36.3× |
| 2023 | 34.1× | 26.9× | 40.7× |
| 2022 | 34.5× | 22.7× | 35.4× |
| 2021 | 30.0× | 16.1× | 30.0× |
| 2020 | 20.7× | 18.1× | 33.1× |
| 2019 | 29.5× | 21.6× | 34.3× |
| 2018 | 29.5× | 28.3× | 58.4× |
| 2017 | 28.2× | 18.6× | 31.8× |
| 2016 | 18.2× | 15.1× | 19.8× |
| 2015 | 19.4× | 19.2× | 81.2× |
| 2014 | 76.3× | 8.3× | 78.8× |
| 2013 | 8.4× | 7.5× | 15.9× |
| 2012 | 11.6× | 7.8× | 12.2× |
| 2011 | 9.6× | 9.3× | 15.1× |
Against its peers
Companies in Medical - Care Facilities nearest Chemed's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| CHEChemed | 21.9× |
| PACSPACS | 15.8× |
| CONConcentra Group Holdings Parent | 19.2× |
| LFSTLifeStance Health | 29.1× |
| SHCSotera Health | 44.9× |
| ENSGEnsign | 24.9× |
| OPCHOption Care Health | 15.6× |
| UHSUniversal Health Services | 12.6× |
| DVADavita | 7.4× |
| BTSGBrightSpring Health Services | 32.6× |
| EHCEncompass Health | 32.7× |
| Peer median | 22.1× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Chemed
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.